TRYP THRAPEUTICS INC - TRYPF STOCK NEWS

Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) has announced that the World Intellectual Property Organization published its international patent application for the intravenous administration of psilocybin and psilocin. This process aims to enhance patient experiences during psychedelic therapy. Key advantages include faster onset and more controllable duration of the psychedelic state, optimal blood levels, and the capability for individualized treatment adjustments. The company is preparing for a conference call on October 4, 2022, to further discuss the implications of this new approach.

Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) announced the filing of two provisional patent applications aimed at expanding its psilocybin-based treatments. One application targets fibromyalgia therapy using psilocybin, while the other enhances the intellectual property for TRP-8803, a leading candidate. CEO Jim Gilligan highlighted efforts to offer new treatment options for chronic pain and eating disorders. The company is preparing for a Phase 2a clinical trial at the University of Michigan, building on promising preclinical results.

Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) announced the filing of a provisional patent for psilocybin's use in treating Binge Eating Disorder (BED) as part of its strategy to enhance intellectual property protections. This filing complements the Phase II S.T.O.P. trial with the University of Florida, showing potential benefits for BED patients. The patent aims to protect its drug candidates TRP-8802 and TRP-8803. The Company focuses on unique therapeutic approaches distinct from competitors, striving for breakthroughs in treating neuropsychiatric disorders with psilocybin-based therapies.

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) announces the appointment of Sid Taubenfeld as Chief Operating Officer, bringing over 20 years of experience in biotech and financial markets. His previous role was CEO of Tikun Olam Pharma, a leading medical cannabis company. Taubenfeld is expected to enhance Tryp's long-term vision and operational efficiency as the company progresses with clinical trials for its psilocybin-based treatments. Tryp focuses on developing psilocybin-related molecules for conditions like binge eating disorder and fibromyalgia.

Tryp Therapeutics (CSE: TRYP; OTCQB: TRYPF) announced initial positive results from its Phase II S.T.O.P. trial, aimed at treating Binge Eating Disorder (BED) with psilocybin-based compound TRP-8802. The first patient dosed showed significant behavioral improvements, including reduced anxiety and weight loss over four weeks after therapy. No drug-related adverse events were reported. The company plans to further investigate TRP-8803, a more advanced formulation intended for BED and other neuropsychiatric disorders. The interim CEO expressed optimism about the results and future studies.

Tryp Therapeutics appoints Chris Ntoumenopoulos to its Board of Directors, enhancing its leadership as it focuses on psilocybin-based compounds for unmet medical needs. Ntoumenopoulos brings extensive experience in raising capital and corporate strategy, making him a vital asset for the company's growth. The company is conducting a Phase II trial for binge eating disorder and an upcoming trial for fibromyalgia. His leadership aims to drive innovative solutions for mental health treatment.

Tryp Therapeutics has initiated its Phase II clinical trial for TRP-8802, a psilocybin-based therapy aimed at treating Binge Eating Disorder (BED). The first patient was dosed in this exploratory study, which aims to assess the safety and preliminary efficacy of psilocybin in combination with psychotherapy. BED affects over 250,000 people annually, and current treatments have shown limited effectiveness. The study collaborates with the University of Florida and includes up to 10 patients. Strong recruitment interest has been noted, marking a significant milestone in psilocybin-assisted therapy.

Tryp Therapeutics has initiated its Phase 2 clinical trial for TRP-8802, the first FDA and DEA-approved study focusing on binge eating disorder. Conducted at the University of Florida, the open-label trial will enroll up to ten patients to evaluate the safety and effectiveness of psilocybin-assisted therapy. This milestone highlights the potential of psilocybin-based treatments in addressing the unmet needs of those suffering from eating disorders, with the aim to create healthier eating behaviors through neuroplasticity.

Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) reported its interim financial results for the period ending November 30, 2021, showing total assets of $2.4 million, including $2.1 million in cash. The company experienced a net loss of $3.0 million. Notably, Tryp submitted Investigational New Drug applications for two Phase 2a studies targeting fibromyalgia and binge eating disorder, which received FDA authorization to proceed. The company's Psilocybin-For-Neuropsychiatric Disorders (PFN™) program aims to develop synthetic psilocybin for chronic pain treatment.